Algert Global LLC Buys 4,540 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Algert Global LLC increased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 13.1% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 39,292 shares of the company’s stock after buying an additional 4,540 shares during the quarter. Algert Global LLC’s holdings in Vaxcyte were worth $4,490,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Riverview Trust Co purchased a new position in Vaxcyte in the third quarter valued at approximately $27,000. Fifth Third Bancorp bought a new position in Vaxcyte during the second quarter worth about $35,000. Blue Trust Inc. increased its stake in shares of Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after purchasing an additional 93 shares in the last quarter. J.Safra Asset Management Corp increased its stake in shares of Vaxcyte by 649.4% in the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock worth $46,000 after purchasing an additional 526 shares in the last quarter. Finally, Quest Partners LLC bought a new stake in shares of Vaxcyte in the second quarter valued at approximately $70,000. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Vaxcyte Stock Up 0.2 %

NASDAQ:PCVX opened at $88.54 on Monday. The business’s 50-day moving average price is $107.89 and its two-hundred day moving average price is $89.57. Vaxcyte, Inc. has a twelve month low of $48.24 and a twelve month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the previous year, the company earned ($0.91) earnings per share. On average, analysts expect that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Jefferies Financial Group lifted their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Bank of America lifted their price target on Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Leerink Partners increased their price objective on Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a report on Tuesday, September 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a report on Wednesday, November 6th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, Vaxcyte presently has an average rating of “Buy” and an average price target of $147.50.

Insider Transactions at Vaxcyte

In other Vaxcyte news, SVP Mikhail Eydelman sold 5,000 shares of Vaxcyte stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $109.27, for a total transaction of $546,350.00. Following the transaction, the senior vice president now directly owns 28,623 shares of the company’s stock, valued at approximately $3,127,635.21. This trade represents a 14.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew Guggenhime sold 42,000 shares of the business’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the completion of the sale, the chief financial officer now owns 90,383 shares of the company’s stock, valued at approximately $10,429,294.37. The trade was a 31.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 102,464 shares of company stock valued at $11,455,576. Insiders own 3.10% of the company’s stock.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.